Skip to main content
. 2016 Apr 22;5(5):e1138200. doi: 10.1080/2162402X.2016.1138200

Figure 3.

Figure 3.

Serum anti-MDM2 autoantibodies in lung cancer and NHC. In Fig. 3A, 3C and 3E, Y-axis represents OD value and X-axis represents serum samples (*p < 0.05; **p < 0.01). (A) Serum anti-MDM2 autoantibodies distribution in NHC (n = 44) and lung cancer patients (n = 50) (p = 0.001). (B) ROC curve analysis using serum anti-MDM2 autoantibodies for discriminating lung cancer patients from NHC in research group (AUC: 0.698, 95% CI: 0.592–0.805, p = 0.001). (C) Serum anti-MDM2 autoantibodies distribution in the validation group including NHC (n = 43) and lung cancer patients (n = 62) (p = 0.005). (D) ROC curve yielded by OD values of serum anti-MDM2 autoantibodies for discriminating lung cancer patients from NHC in the validation group (AUC: 0.777, 95% CI: 0.689–0.865, p < 0.001). (E) Serum anti-MDM2 autoantibodies distribution and in NHC and lung cancer patients with different TNM stage. (F) ROC curve yielded by OD values of anti-MDM2 autoantibodies in discriminating stage I lung cancer patients from NHC (AUC: 0.703; 95% CI: 0.5800–0.827, p = 0.003). (G) ROC curve yielded by OD values of anti-MDM2 autoantibodies in discriminating stage II lung cancer patients from NHC (AUC: 0.622; 95% CI: 0.432–0.812, p = 0.161). (H) ROC curve yielded by OD values of anti-MDM2 autoantibodies in discriminating stage I lung cancer patients from NHC (AUC: 0.866; 95% CI: 0.741–0.991, p = 0.004). Note: LC1: 50 lung cancer patients from research group. LC2: 62 lung cancer patients from validation group.